Orfonyx Bio develops genetic medicines that increase protein production by targeting regulatory elements in the untranslated regions of genes. Using its proprietary APEX antisense oligonucleotide platform, the company blocks repressive sequence motifs to boost expression of specific proteins, creating therapies for diseases with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are caused by insufficient levels of specific proteins, yet existing therapies lack mechanisms to selectively increase endogenous protein production. Traditional approaches such as gene therapy or protein replacement can be limited by delivery challenges, immunogenicity, and lack of precise control over expression levels.
Solution
Orfonyx Bio creates a new class of genetic medicines that up‑regulate target proteins by modulating regulatory elements in the untranslated regions (UTRs) of messenger RNA. Their proprietary APEX (Activation of Protein Expression) antisense oligonucleotide platform binds to repressive sequence motifs within UTRs, blocking their inhibitory effect and thereby enhancing translation of the native gene. This antisense approach enables precise, dose‑dependent elevation of protein expression without introducing exogenous DNA or proteins. By leveraging computational design to identify optimal target sites, Orfonyx can develop therapies for a range of conditions where protein deficiency is a key driver, offering a potentially safer and more controllable alternative to existing modalities.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to develop treatments for diseases driven by protein insufficiency, as well as research institutions pursuing precision up‑regulation of specific genes.
Features
- APEX antisense oligonucleotides specifically target repressive motifs in 5' and 3' untranslated regions to boost translation efficiency
- Proprietary computational pipeline identifies optimal UTR regulatory elements for each therapeutic target
- Chemically modified oligonucleotides provide enhanced stability and tissue penetration while minimizing off‑target effects
- Platform enables dose‑tunable protein up‑regulation, allowing fine control over therapeutic windows
- Designed for systemic or localized delivery, compatible with existing oligonucleotide formulation technologies